NS Pharma, Inc.

NS Pharma is a wholly owned subsidiary of Nippon Shinyaku that advances rare-disease therapies addressing unmet medical needs. It serves as an in-house research center and a commercialization partner to clinical-stage biotechnology companies. Its work includes therapies for Duchenne muscular dystrophy, Hunter syndrome, and EGPA, as well as developing exon-skipping technology to bring promising treatments to patients.